Jerry F Brown1, Kathleen Rowe2, Peter Zacharias3, James van Hasselt3, John M Dye4, David A Wohl5, William A Fischer5, Coleen K Cunningham6, Nathan M Thielman6, David L Hoover7. 1. Eternal Love Winning Africa Hospital, Paynesville, Liberia. 2. Blood Centers of America, West Warwick, RI. 3. Safe Blood for Africa Foundation, Washington, DC. 4. Division of Virology, United States Army Medical Research Institute of Infectious Disease, Frederick, MD. 5. University of North Carolina School of Medicine, Chapel Hill, NC. 6. Duke University School of Medicine, Durham, NC. 7. Clinical Research Management, Inc, OH, Hinckley.
Abstract
PURPOSE: This report describes initiation of apheresis capability in Liberia, Africa to support a clinical trial of convalescent plasma therapy for Ebola Virus Disease. METHODS: A bloodmobile was outfitted in the United States as a four-bed apheresis unit with capabilities including pathogen reduction, electronic blood establishment computer system, designated areas for donor counseling and laboratory testing, and onboard electrical power generation. After air transport to Liberia, the bloodmobile was positioned at ELWA Hospital, Monrovia, and connected to the hospital's power grid. Liberian staff were trained to conduct donor screening, which included questionnaire and onsite blood typing and transfusion transmitted infection (TTI) testing, and plasma collection and processing. RESULTS: The bloodmobile was operational within 3 weeks after arrival of the advance team. Of 101 donors who passed the pre-screening questionnaire, 32 were deferred. Twenty-eight of ninty-nine tested survivors were deferred for positive transfusion transmitted infection (TTI) tests; twenty-one were positive for hepatitis B, hepatitis C, or human immunodeficiency virus. The majority of donors had type O blood; all but one were Rh positive. Forty-three survivors donated at least once; eighty-nine apheresis attempts resulted in eighty-one successful collections. CONCLUSIONS: Apheresis capability was emergently established in Liberia to support an efficacy trial of Ebola Convalescent Plasma. Extensive cooperation among multinational team members, engineers, logisticians, and blood safety technical personnel at the operational site was required to surmount challenges to execution posed by logistical factors. The high proportion of positive TTI tests supported the use of a pathogen reduction system to enhance product safety. J. Clin. Apheresis 32:175-181, 2017.
PURPOSE: This report describes initiation of apheresis capability in Liberia, Africa to support a clinical trial of convalescent plasma therapy for Ebola Virus Disease. METHODS: A bloodmobile was outfitted in the United States as a four-bed apheresis unit with capabilities including pathogen reduction, electronic blood establishment computer system, designated areas for donor counseling and laboratory testing, and onboard electrical power generation. After air transport to Liberia, the bloodmobile was positioned at ELWA Hospital, Monrovia, and connected to the hospital's power grid. Liberian staff were trained to conduct donor screening, which included questionnaire and onsite blood typing and transfusion transmitted infection (TTI) testing, and plasma collection and processing. RESULTS: The bloodmobile was operational within 3 weeks after arrival of the advance team. Of 101 donors who passed the pre-screening questionnaire, 32 were deferred. Twenty-eight of ninty-nine tested survivors were deferred for positive transfusion transmitted infection (TTI) tests; twenty-one were positive for hepatitis B, hepatitis C, or human immunodeficiency virus. The majority of donors had type O blood; all but one were Rh positive. Forty-three survivors donated at least once; eighty-nine apheresis attempts resulted in eighty-one successful collections. CONCLUSIONS: Apheresis capability was emergently established in Liberia to support an efficacy trial of Ebola Convalescent Plasma. Extensive cooperation among multinational team members, engineers, logisticians, and blood safety technical personnel at the operational site was required to surmount challenges to execution posed by logistical factors. The high proportion of positive TTI tests supported the use of a pathogen reduction system to enhance product safety. J. Clin. Apheresis 32:175-181, 2017.
Authors: Daniel S Chertow; Christian Kleine; Jeffrey K Edwards; Roberto Scaini; Ruggero Giuliani; Armand Sprecher Journal: N Engl J Med Date: 2014-11-05 Impact factor: 91.245
Authors: John M Dye; Andrew S Herbert; Ana I Kuehne; James F Barth; Majidat A Muhammad; Samantha E Zak; Ramon A Ortiz; Laura I Prugar; William D Pratt Journal: Proc Natl Acad Sci U S A Date: 2012-03-12 Impact factor: 11.205
Authors: Jay B Varkey; Jessica G Shantha; Ian Crozier; Colleen S Kraft; G Marshall Lyon; Aneesh K Mehta; Gokul Kumar; Justine R Smith; Markus H Kainulainen; Shannon Whitmer; Ute Ströher; Timothy M Uyeki; Bruce S Ribner; Steven Yeh Journal: N Engl J Med Date: 2015-05-07 Impact factor: 91.245
Authors: Robert A Fowler; Thomas Fletcher; William A Fischer; Francois Lamontagne; Shevin Jacob; David Brett-Major; James V Lawler; Frederique A Jacquerioz; Catherine Houlihan; Tim O'Dempsey; Mauricio Ferri; Takuya Adachi; Marie-Claire Lamah; Elhadj Ibrahima Bah; Thierry Mayet; John Schieffelin; Susan L McLellan; Mikiko Senga; Yasuyuki Kato; Christophe Clement; Simon Mardel; Rosa Constanza Vallenas Bejar De Villar; Nahoko Shindo; Daniel Bausch Journal: Am J Respir Crit Care Med Date: 2014-10-01 Impact factor: 21.405
Authors: Johan van Griensven; Tansy Edwards; Xavier de Lamballerie; Malcolm G Semple; Pierre Gallian; Sylvain Baize; Peter W Horby; Hervé Raoul; N'Faly Magassouba; Annick Antierens; Carolyn Lomas; Ousmane Faye; Amadou A Sall; Katrien Fransen; Jozefien Buyze; Raffaella Ravinetto; Pierre Tiberghien; Yves Claeys; Maaike De Crop; Lutgarde Lynen; Elhadj Ibrahima Bah; Peter G Smith; Alexandre Delamou; Anja De Weggheleire; Nyankoye Haba Journal: N Engl J Med Date: 2016-01-07 Impact factor: 91.245
Authors: Jerry F Brown; John M Dye; Sam Tozay; Gertrude Jeh-Mulbah; David A Wohl; William A Fischer; Coleen K Cunningham; Kathleen Rowe; Peter Zacharias; James van Hasselt; David A Norwood; Nathan M Thielman; Samantha E Zak; David L Hoover Journal: J Infect Dis Date: 2018-07-13 Impact factor: 5.226
Authors: Kenneth Danh; Donna Grace Karp; Peter V Robinson; David Seftel; Mars Stone; Graham Simmons; Anil Bagri; Martin Schreibman; Andreas Buser; Andreas Holbro; Manuel Battegay; Laurence M Corash; Carl Hanson; Cheng-Ting Tsai Journal: medRxiv Date: 2020-06-02
Authors: Kenneth Danh; Donna Grace Karp; Malvika Singhal; Akshaya Tankasala; David Gebhart; Felipe de Jesus Cortez; Devangkumar Tandel; Peter V Robinson; David Seftel; Mars Stone; Graham Simmons; Anil Bagri; Martin A Schreiber; Andreas Buser; Andreas Holbro; Manuel Battegay; Mary Kate Morris; Carl Hanson; John R Mills; Dane Granger; Elitza S Theel; James R Stubbs; Laurence M Corash; Cheng-Ting Tsai Journal: Nat Commun Date: 2022-07-21 Impact factor: 17.694
Authors: Laura Skrip; Karim Derra; Mikaila Kaboré; Navideh Noori; Adama Gansané; Innocent Valéa; Halidou Tinto; Bicaba W Brice; Mollie Van Gordon; Brittany Hagedorn; Hervé Hien; Benjamin M Althouse; Edward A Wenger; André Lin Ouédraogo Journal: Int J Infect Dis Date: 2020-09-26 Impact factor: 3.623